Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab maintenance study in moderately to severely active ulcerative colitis
NL-OMON55664Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Mirikizumab maintenance, Placebo maintenance after mirikizumab induction and Placebo continuation after placebo induction (3 arms). Primary endpoint: Clinical remission at Week 40 among patients induced into clinical remission with mirikizumab induction treatment. Started Aug 2019; status: active, not recruiting.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON55664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55664.